logo

For the Inventor, By the Inventor

Stonington, CT, United States of America

Mark A Guadliana

This inventor holds 6 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 1983-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark A Guadliana. Retrieved from https://idiyas.com/inventor/mark-a-guadliana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Gales Ferry, CT (US) (1983)
  • Stonington, CT (US) (1996 - 2002)

Company Filing History:

goldMedal6 out of 4,486 
 
Pfizer Corporation
 patents

Years Active: 1983-2002

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6372781 - Compounds for treating gastroduodenal diseases (2002-04-16),
2. 6174710 - Spirolaxine derivatives for treating gastrobuodenal diseases (2001-01-16),
3. 6074855 - Process for preparing spirolaxine and spirolaxine methyl ether (2000-06-13),
4. 5849730 - Process for preparing demethylrapamycins (1998-12-15),
5. 5494820 - Streptomyces braegensis strain and its cultivation in a process for (1996-02-27),
6. 4382085 - 4'-Epi erythromycin A and derivatives thereof as useful antibacterial (1983-05-03),

Title: The Innovative Contributions of Mark A. Guadliana

Introduction

Mark A. Guadliana is a notable inventor based in Stonington, Connecticut. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of gastroduodenal diseases. With a total of six patents to his name, Guadliana's work has the potential to impact many lives.

Latest Patents

Among his latest patents is a groundbreaking compound for treating gastroduodenal diseases, known as Spirolaxine. This compound, represented by the formula (I) wherein R is H, along with novel compounds where R is (C-C) alkyl or CH(CH)CO, is designed to address conditions such as gastric ulcers, duodenal ulcers, and gastric cancer. Spirolaxine and its methyl ether are isolated from the fermentation of ATCC 74278. Additionally, these compounds can be used in combination with H antagonists, colloidal bismuth subcitrate, and other antibiotics, showcasing their versatility in treatment.

Career Highlights

Guadliana's career is marked by his dedication to pharmaceutical innovation. His work at Pfizer Corporation has allowed him to focus on developing effective treatments for complex medical conditions. His patents reflect a commitment to advancing medical science and improving patient outcomes.

Collaborations

Throughout his career, Guadliana has collaborated with esteemed colleagues, including Liang H. Huang and Takushi Kaneko. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Mark A. Guadliana's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving healthcare. His work continues to pave the way for new treatments that can significantly benefit patients suffering from gastroduodenal diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…